COVID Vaccine For Kids Ages 5 To 11 Is Safe And Effective, Pfizer Says

.

A health worker administers a dose of a Pfizer COVID-19 vaccine during a vaccination center earlier this month at the Reading Area Community College in Reading, Pa

Matt Rourke/AP

conceal caption toggle caption Matt Rourke/AP

And even if the FDA grants that permission, Dr. Francis Collins, director of the National Institutes of Health, recently told NPR that caretakers and moms and dads will likely have to wait till the end of 2021 prior to a COVID-19 vaccine is totally authorized for young kids ages 5 to 11. Trial results for children under 5 years of age might come later on this year, the pharmaceutical business stated.

The very first results from the highly prepared for trial studying the effectiveness and security of the Pfizer and BioNTech COVID-19 vaccine for kids ages 5 to 11 revealed promising results. The pharmaceutical companies stated early outcomes of their trial indicate the vaccine is safe for kids and develops a strong antibody response versus the infection. These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we prepare to send them to the FDA and other regulators with seriousness,” stated Albert Bourla, the chairman and CEO for Pfizer.

A health worker administers a dosage of a Pfizer COVID-19 vaccine during a vaccination center previously this month at the Reading Area Community College in Reading, Pa

Regardless of the strong results, it will be some time before the general public can see an official rollout of vaccines for children ages 5 to 11. And even if the FDA grants that permission, Dr. Francis Collins, director of the National Institutes of Health, just recently told NPR that caregivers and parents will likely have to wait till the end of 2021 before a COVID-19 vaccine is completely authorized for young kids ages 5 to 11.

The very first outcomes from the highly expected trial studying the effectiveness and safety of the Pfizer and BioNTech COVID-19 vaccine for children ages 5 to 11 showed promising outcomes. These trial results offer a strong structure for looking for authorization of our vaccine for children 5 to 11 years old, and we prepare to send them to the FDA and other regulators with urgency,” stated Albert Bourla, the chairman and CEO for Pfizer.

.

” Over the previous nine months, hundreds of countless people ages 12 and older from all over the world have received our COVID-19 vaccine. We are eager to extend the defense managed by the vaccine to this more youthful population, based on regulative authorization, specifically as we track the spread of the Delta variation and the significant danger it presents to kids,” Bourla said in a declaration. Despite the strong outcomes, it will be some time prior to the basic public can see an official rollout of vaccines for children ages 5 to 11. Once analysis of the trial is completed, Pfizer and BioNTech will submit the results “in the near term” to the Food and Drug Administration for review and possible emergency use authorization.

Leave a Reply

Your email address will not be published. Required fields are marked *